These data indicate that cetuximab-induced antitumor activity could be monitored by 64Cu-PCTA-cetuximab, immuno-PET agent, which represents the relative level of EGFR expression in ESCC tumors. Here, EGFR is linked to esophageal squamous cell carcinoma.